0001104659-21-129900.txt : 20211026 0001104659-21-129900.hdr.sgml : 20211026 20211026133940 ACCESSION NUMBER: 0001104659-21-129900 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20211026 DATE AS OF CHANGE: 20211026 EFFECTIVENESS DATE: 20211026 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Petros Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001815903 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 851410058 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-418562 FILM NUMBER: 211347577 BUSINESS ADDRESS: STREET 1: 1185 AVENUE OF THE AMERICAS, 3RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: 973-242-0005 MAIL ADDRESS: STREET 1: 1185 AVENUE OF THE AMERICAS, 3RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 D 1 primary_doc.xml X0708 D LIVE 0001815903 Petros Pharmaceuticals, Inc. 1185 AVENUE OF THE AMERICAS, SUITE 249 NEW YORK NY NEW YORK 10036 (973) 242-0005 DELAWARE None None Corporation true 2020 Mitchell Arnold 1185 Avenue of the Americas, Suite 249 New York NY NEW YORK 10036 Executive Officer Vice President of Finance and Principal Accounting Officer Fady Boctor 1185 Avenue of the Americas, Suite 249 New York NY NEW YORK 10036 Executive Officer President and Chief Commercial Officer John D. Shulman 1185 Avenue of the Americas, Suite 249 New York NY NEW YORK 10036 Director Joshua N. Silverman 1185 Avenue of the Americas, Suite 249 New York NY NEW YORK 10036 Director Bruce T. Bernstein 1185 Avenue of the Americas, Suite 249 New York NY NEW YORK 10036 Director Gregory Bradley 1185 Avenue of the Americas, Suite 249 New York NY NEW YORK 10036 Director Wayne R. Walker 1185 Avenue of the Americas, Suite 249 New York NY NEW YORK 10036 Director Andrew Gesek 1185 Avenue of the Americas, Suite 249 New York NY NEW YORK 10036 Executive Officer President, Timm Medical Pharmaceuticals Decline to Disclose 06b false 2021-10-13 false true true false 0 5922951 0 5922951 Represents warrants to purchase up to 3,323,616 shares of common stock at $1.715/share and warrants to purchase up to 130,000 shares of common stock at $1.715/share issued to financial advisors in connection with RD offering that closed on 10/15/2021. false 10 0 0 0 false Petros Pharmaceuticals, Inc. /s/ Mitchell Arnold Mitchell Arnold Vice President of Finance and Principal Accounting Officer 2021-10-22